Callisto Stockholders Approve Merger With Synergy Pharmaceuticals

Callisto Stockholders Approve Merger With Synergy Pharmaceuticals

NEW YORK, Jan. 15, 2013 (GLOBE NEWSWIRE) -- Callisto Pharmaceuticals, Inc.
(OTCQB:CLSP) ("Callisto") today announced that it convened its special meeting
of stockholders yesterday and it has received the necessary approvals from its
stockholders to authorize Callisto's merger with and into Synergy
Pharmaceuticals Inc. ("Synergy") pursuant to the previously announced
Agreement and Plan of Merger, dated July 20, 2012, as amended on October 15,
2012.Callisto and Synergy expect to close the merger as soon as practicable.

About Callisto Pharmaceuticals Inc.

Callisto is a development stage biopharmaceutical company. All of Callisto's
drug candidates, currently plecanatide and SP-333 to treat GI disorders and
diseases, are being developed exclusively by Synergy.

CONTACT: Investor Contact:
         Danielle Spangler
         The Trout Group
         synergy@troutgroup.com
         (646) 378-2924